Pregnancy during TNFalpha antagonist therapy: beware the rifampin-oral contraceptive interaction. Report of two cases.
We report two cases of pregnancy in patients taking TNFalpha antagonists for chronic inflammatory joint disease. A factor in both pregnancies was the use of rifampin concomitantly with a combined oral contraceptive. Both patients were taking rifampin and isoniazid for tuberculosis prophylaxis in compliance with French recommendations for patients with positive intradermal tuberculin tests who are scheduled to receive biotherapeutic agents.
Wibaux
Cécile
C
Service de rhumatologie, hôpital Roger-Salengro, CHRU de Lille, université de Lille-2, rue Emile-Laine, 59037 Lille cedex, France. c-wibaux@chru-lille.fr
Andrei
Irina
I
Paccou
Julien
J
Philippe
Peggy
P
Biver
Emmanuel
E
Duquesnoy
Bernard
B
Flipo
René Marc
RM
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000009:adverse effects*; D003276:Contraceptives, Oral / Q000009:adverse effects*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007538:Isoniazid / Q000009:adverse effects; D011247:Pregnancy; D012293:Rifampin / Q000009:adverse effects*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000276:immunology; D014397:Tuberculosis, Pulmonary / Q000276:immunology / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D018501:Antirheumatic Agents; D000995:Antitubercular Agents; D003276:Contraceptives, Oral; D014409:Tumor Necrosis Factor-alpha; D007538:Isoniazid; D012293:Rifampin